Summary: More than a billion people in the world currently suffer from hypertension. More than 400 million people suffer from chronic obstructive pulmonary disease, and more than 260 million from asthma. Such a high prevalence of each of these diseases makes it increasingly challenging to provide hypotensive treatment to patients with chronic respiratory diseases. Such comorbidity requires the physician not only to effectively treat each of these diseases separately but, most importantly, to effectively treat both diseases at the same time. The success of such management requires knowledge of the pathophysiology of hypertension and the processes occurring at the cellular level in the airways. Only
such an analysis can transparently demonstrate the efficacy and safety of AT1 receptor antagonists and dihydropyridine calcium channel blockers, explain the caution needed during treatment with diuretics, and expose the risks associated with β-blocker therapy in this group of patients.